RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
Completed · Phase 1
Conditions studied: Cancer
In brief
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of RAV12 in treating patients with metastatic or recurrent adenocarcinoma.
Key facts
- Study ID
- NCT00101972
- Run by
- MacroGenics
- People needed
- 53
- Starts
- 2004-12-01
- Expected to finish
- 2008-05-01
- Last updated by the study team
- 2022-02-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Premiere Oncology — Santa Monica, California, United States
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center — Washington D.C., District of Columbia, United States
- University of Miami Sylvester Comprehensive Cancer Center - Miami — Miami, Florida, United States
- Fox Chase Cancer Center - Philadelphia — Philadelphia, Pennsylvania, United States
- Sarah Cannon Cancer Center at Centennial Medical Center — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.